<DOC>
	<DOCNO>NCT02896296</DOCNO>
	<brief_summary>Study provide ongoing treatment RBP-6000 safety monitoring subject complete RB-US-13-0003 study new treatment venue identify .</brief_summary>
	<brief_title>Open-Label Treatment Extension Study</brief_title>
	<detailed_description>This multi-center , open-label , RBP-6000 treatment extension study subject complete End Study ( EOS ) procedures study RB-US-13-0003 eligible . EOS assessment complete RB-US-13-0003 EOS visit serve screen visit study . In addition , subject request complete Columbia Suicide Severity Rating Scale ( C-SSRS ) baseline survey medical history obtain . The Informed consent may share subject 2 month prior RB-US-13-0003 EOS visit , however sign assessment EOS visit complete . On Day 1 , eligible subject receive subcutaneous ( SC ) injection RBP-6000 low high dose base medical judgment discretion investigator . After injection , vital sign injection site assess . Prior depart site , subject also assess adverse event ( AEs ) use concomitant medication ( ConMeds ) . Subjects return site monthly injection visit every 28 day ( -2 / +7 day ) total 6 injection . At subsequent visit ( Injections 2 6 ) follow procedure / assessment perform : urine pregnancy test perform female subject childbearing potential injection ; previous injection site assess potential reaction evidence attempt remove depot ; vital sign collect pre post injection ; RBP-6000 injection , urine drug screen ( UDS ) ; C-SSRS since last visit assessment , counsel ( manual-guided behavioral therapy ) ; use ConMeds ; assessment AEs . Laboratory test ( hematology , chemistry urinalysis ) may request Investigator ad-hoc basis order ass AEs . A subject 's alternative treatment option assess least two month EOS visit . At EOS , follow assessment perform : urine pregnancy test perform female subject childbearing potential ; vital sign ; previous injection site assess potential reaction evidence attempt remove depot ; UDS ; C-SSRS since last visit assessment , counsel ( manual-guided behavioral therapy ) ; use ConMeds ; assessment AEs ; brief physical exam ; height body weight measure subject 's body mass index ( BMI ) hip waist ratio calculate ; laboratory test ( hematology , chemistry , urinalysis ) . Subjects contact telephone approximately 4 week EOS safety follow-up assessment AEs use ConMeds .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Provide write consent participate study . 2 . Completed End Study Visit RBUS130003 study . 3 . Be consider eligible medical judgment Investigator . 4 . Females : Women childbearing potential ( defined woman surgically sterile postmenopausal least 1 year prior ICF ) must negative pregnancy test prior enrollment must agree use medically acceptable mean contraception screen least 6 month last dose investigational medicinal product ( IMP ) . Males : Subjects female partner childbearing potential must agree use medically acceptable contraception sign ICF least 6 month last dose IMP . Male subject must also agree donate sperm study 6 month receive last dose IMP . 5 . Subjects must agree take buprenorphine product administer current study throughout participation study . 6 . Subjects must willing adhere study procedure . 1 . Subject compliance issue participation RBUS130003 study , opinion Investigator , could potentially compromise subject safety . 2 . Women childbearing potential positive pregnancy test RBUS130003 EOS , pregnant breastfeeding , seek pregnancy , fail use adequate contraceptive method study . 3 . History suicidal ideation within 28 day prior sign ICF evidence answer `` yes ' question 4 5 suicidal ideation portion CSSRS `` screening/baseline '' history suicide attempt ( per CSSRS ) 6 month prior ICF . 4 . Taking cytochrome P450 3A4 2C8 inducer inhibitor , selfreported additional buprenorphine , OTC herbal supplement potential prolong QTc per section 6.10.1 within 28 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>